For research use only. Not for therapeutic Use.
Oltipraz（Cat No.:I004425）is a synthetic dithiolethione compound known for its chemopreventive properties, particularly in liver and gastrointestinal cancers. By inducing phase II detoxification enzymes, Oltipraz enhances the body’s ability to metabolize and eliminate carcinogens, thereby reducing cancer risk. Additionally, it exhibits antioxidant activity, protecting cells from oxidative stress. Clinical studies have investigated its potential in chemoprevention and treatment of various cancers, as well as its effects on hepatic health. Oltipraz continues to be explored for its therapeutic applications and mechanisms in cancer prevention and liver disease management.
| Catalog Number | I004425 |
| CAS Number | 64224-21-1 |
| Synonyms | NSC 347901;RP 35972 |
| Molecular Formula | C8H6N2S3 |
| Purity | ≥95% |
| Target | HIF-1α |
| Solubility | 10 mM in DMSO |
| Storage | 2-8°C |
| IC50 | 10 μM |
| IUPAC Name | 4-methyl-5-pyrazin-2-yldithiole-3-thione |
| InChI | InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3 |
| InChIKey | CKNAQFVBEHDJQV-UHFFFAOYSA-N |
| SMILES | CC1=C(SSC1=S)C2=NC=CN=C2 |
| Reference | </br>1:Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Kim W, Kim BG, Lee JS, Lee CK, Yeon JE, Chang MS, Kim JH, Kim H, Yi S, Lee J, Cho JY, Kim SG, Lee JH, Kim YJ.Aliment Pharmacol Ther. 2017 Apr;45(8):1073-1083. doi: 10.1111/apt.13981. Epub 2017 Feb 22. PMID: 28225186 </br>2:4,5-Diaryl-3H-1,2-dithiole-3-thiones and related compounds as combretastatin A-4/oltipraz hybrids: Synthesis, molecular modelling and evaluation as antiproliferative agents and inhibitors of tubulin. Wang Z, Qi H, Shen Q, Lu G, Li M, Bao K, Wu Y, Zhang W.Eur J Med Chem. 2016 Oct 21;122:520-9. doi: 10.1016/j.ejmech.2016.06.055. Epub 2016 Jul 1. PMID: 27428395 </br>3:The Effects of Oltipraz on Tissue Regeneration in the Process of Wound Healing: A Stereological Study. Noorafshan A, Kardeh S, Ashkani-Esfahani S, Namazi MR, Saleh E.Bull Emerg Trauma. 2014 Oct;2(4):161-5. PMID: 27162890 Free PMC Article</br>4:Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice. Weerachayaphorn J, Luo Y, Mennone A, Soroka CJ, Harry K, Boyer JL.J Hepatol. 2014 Jan;60(1):160-6. doi: 10.1016/j.jhep.2013.08.015. Epub 2013 Aug 23. PMID: 23978715 Free PMC Article</br>5:The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, Ishida K, Watanabe T, Shimizu T, Shimokawa H, Okada Y, Yamamoto M, Kondo T.Am J Respir Cell Mol Biol. 2013 Aug;49(2):324-33. doi: 10.1165/rcmb.2011-0396OC. PMID: 23590302 </br>6:An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK. Kim TH, Eom JS, Lee CG, Yang YM, Lee YS, Kim SG.Br J Pharmacol. 2013 Apr;168(7):1647-61. doi: 10.1111/bph.12057. PMID: 23145499 Free PMC Article</br>7:Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction. Kang SG, Lee WH, Lee YH, Lee YS, Kim SG.Carcinogenesis. 2012 Mar;33(3):661-9. doi: 10.1093/carcin/bgr320. Epub 2012 Jan 4. PMID: 22223846 </br>8:Quantification of oltipraz using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in rat plasma. Lee JH, Lim H, Kim DG, Park DH, Woo YA, Noh HJ, Jin QR, Lee KR, Lee GW, Kim CY.J Pharm Biomed Anal. 2011 Nov 1;56(3):623-6. doi: 10.1016/j.jpba.2011.06.014. Epub 2011 Jun 25. PMID: 21757314 </br>9:Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial. Kim SG, Kim YM, Choi JY, Han JY, Jang JW, Cho SH, Um SH, Chon CY, Lee DH, Jang JJ, Yu E, Lee YS.J Pharm Pharmacol. 2011 May;63(5):627-35. doi: 10.1111/j.2042-7158.2011.01259.x. Epub 2011 Mar 14. PMID: 21492164 </br>10:Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, Fantus IG, Jin T.Diabetologia. 2011 Apr;54(4):922-34. doi: 10.1007/s00125-010-2001-8. Epub 2010 Dec 16. Erratum in: Diabetologia. 2011 Apr;54(4):989. PMID: 21161163 |
